Articles tagged with Drug Therapy
The Japanese version of the rPATD questionnaire has been validated to assess attitudes towards medication reductions among older adults and their caregivers in Japan. The tool is reliable, valid, and easily understood, facilitating shared decision-making between healthcare providers and patients.
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers analyzed medical records of 1,269 elderly patients with advanced cancer to find that over 70% were prescribed potentially inappropriate medications (PIMs), which declined closer to death. PIM discontinuation was more common among female patients, those with polypharmacy, and palliative care unit admissions.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
A new study by the University of Texas at Arlington examines how updated CDC guidelines can help nurse practitioners reduce opioid misuse and protect patients. The guidelines emphasize individualized care, clinical judgment, and ongoing reassessment to ensure safe prescribing practices.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
The FDA's regulation of mifepristone involves characterizing its decision-making process and rationale for key components. The agency's approach has evolved over time, with notable changes to its regulatory framework.
Researchers have made a groundbreaking discovery about how bacteria swim upstream to cause infections, pointing to new designs for biomedical devices that can prevent contamination. The study found that wider channels with faster counterflows are more prone to invasion, but sharp corner designs can inhibit bacterial growth.
A new study found that 4.9 million adults in Great Britain have recently used a drug to support weight loss or were interested in using one in the near future. The usage far exceeds NHS England's initial goal of prescribing these drugs to 220,000 people over three years.
Researchers at the University of Illinois discovered that propofol, a common anesthetic agent, can improve cognitive function after surgery in older individuals. Additionally, intranasal insulin was found to mitigate age-related memory impairment by modulating neuroinflammatory mechanisms.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
Acute sepsis alters fluid kinetics and creates a 'third space' resistant to adrenergic modulation, leading to maldistribution of crystalloid fluid. Vasoactive drugs have limited effect on fluid distribution in septic sheep compared to healthy animals.
Researchers at UVA Health System discover how traumatic brain injury increases Alzheimer's risk and find a potential prevention strategy using a hollowed-out virus to deliver repair supplies. The approach could help limit neurodegeneration and potentially prevent other neurological diseases.
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
Combocat integrates miniaturized drug dispensing with machine learning to efficiently uncover promising drug combinations. The platform's capabilities were published in Nature Communications, demonstrating its potential for scaling up drug combination screening.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
A new study found that annual ADHD prescription rates increased by 157 percent in Ontario from 2015 to 2023, with significant increases in females and younger age groups. The authors suggest a potential rise in true cases of ADHD, improved diagnosis, or misdiagnosis as contributing factors.
Researchers at Martin Luther University Halle-Wittenberg have developed a promising new substance that inhibits the ability of tuberculosis bacteria to produce energy and causes them to die. The compound, PRP020, targets the pathogen's ATP synthase but attacks a different site than existing drugs like bedaquiline.
Scientists have developed an experimental drug called TY1 that repairs DNA damage and promotes healing in damaged tissue. The breakthrough could lead to new treatments for heart attacks, autoimmune diseases, and other conditions.
A growing trend of antipsychotic medication prescription increases in older U.S. adults, with long-term care pharmacies being a primary source. Non-psychiatrist prescribers contribute to the trend, highlighting concerns over medication accessibility and oversight.
Researchers at the University of Iowa Health Care have developed a new class of medication, pegcetacoplan, which directly targets the root cause of C3 glomerulopathy, a rare and severe kidney disease. The treatment has shown significant results, with up to 67% of children achieving complete remission and stabilization of kidney function.
Researchers tracked 120 older veterans taking gabapentinoids and loop diuretics, finding that only 4 doctors correctly identified the gabapentinoids as the cause of leg swelling. The study highlights the dangers of 'prescribing cascades' and emphasizes the need for regular monitoring and alternative treatment options.
A new study found that long-term antidepressant use has increased by nearly 20% among young people aged 10-24, raising concerns about potential overprescribing. The study also found no meaningful improvement in efforts to wean patients off antidepressants, highlighting the need for a stronger framework for safely tapering medications.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack by delivering interleukin-4 directly to damaged heart tissue. The patch uses a microneedle system to promote repair and improve heart function without affecting the rest of the body.
A study comparing GLP-1 RAs found that all three drugs are relatively safe options for patients with type 2 diabetes, with minimal differences in kidney and cardiovascular risks. Liraglutide had a lower risk of all-cause mortality compared to dulaglutide.
Researchers at Florida Atlantic University have discovered a potential new treatment for Alzheimer's disease by targeting muscle protein Cathepsin B. The study found that increasing Ctsb in muscle tissue may offer protection against the effects of AD and promote brain cell growth, restoring protein balance and rebalancing brain activity.
A new compound MCH11, a monoacylglycerol lipase inhibitor, shows promising effects in reducing alcohol consumption and motivation to drink in mice. The molecule exhibits anxiolytic and antidepressant properties with sex-dependent efficacy, correcting genetic alterations associated with alcohol use disorder.
A study by Aston University academics found that while access to antiseizure medication is expanding globally, it's not always prescribed safely. Valproate, widely used, poses significant risks during pregnancy, including birth defects and neurodevelopmental problems.
Researchers analyzed insurance claims data from US health insurers to demonstrate the cardiovascular benefits of semaglutide and tirzepatide. Both GLP-1 drugs provide cardioprotective effects, reducing the risk of stroke and heart attack by 18% and 13%, respectively.
Researchers at UVA School of Medicine found that the breakdown of protective brain structures called perineuronal nets leads to social memory loss in Alzheimer's patients. Preventing the degradation of these nets may lead to new treatments to prevent or delay the disease.
Researchers from Intermountain Health have found that GLP-1 receptor agonists do not increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides. Patients taking these medications had a four times lower risk of developing pancreatitis compared to those not on the medication.
A new AI model uses machine learning to predict drug toxicity in humans by identifying biological differences between cells, mice, and humans. The model improved predictive power over existing state-of-the-art models and demonstrated practicality in predicting market withdrawal due to toxicity.
West Virginia University researchers are working with local partners to stop drug use in youth before it starts. They will expand an existing pilot project to encompass 140 schools in 36 rural counties, tailored to individual community needs.
A recent study at the University of Gothenburg discovered that two medications, cholestyramine and colesevelam, can rapidly eliminate perfluoroalkyl substances (PFAS) from the body. The findings suggest a potential therapeutic application for these medicines in reducing PFAS levels.
The study highlights the frequent use of aerosol therapy in critically ill patients with acute respiratory distress syndrome (ARDS), with bronchodilators being the most commonly prescribed drugs. However, the lack of sound scientific evidence and randomized controlled trials suggests that standardized protocols are needed to align clin...
A University of East Anglia study found that treating patients at home with IV antibiotics can save the NHS over £3,500 per patient and potentially free-up vital hospital beds. The treatment involves having antibiotics prepared at home and continuously delivered into the bloodstream by an elastomeric pump.
Scientists found that activating specific neurons in the claustrum region of male rats under psychedelic exposure strengthens connections to areas implicated in psychiatric diseases, potentially explaining how psychedelics improve memory and symptoms. The study suggests a new pathway for understanding psychedelics' therapeutic effects.
The FDA has approved elinzanetant for treating hot flashes and night sweats in postmenopausal women. The drug significantly reduces the frequency and severity of symptoms while improving sleep quality and quality of life.
A UH crystals expert has shown how to bend and twist crystals without physical force, using a molecule called a tautomer. This discovery has potential applications in drug delivery and material properties, such as optoelectronics and soft robotics.
A new study published in The Lancet found that semaglutide, a 'weight loss' drug, can help prevent heart attacks and other major cardiac events, regardless of the amount of weight people lose. The study suggests there are multiple ways the drug benefits the heart, beyond its protective effect on cardiovascular health.
A recent study found that 44% of people with chronic conditions experience medication-related burden, which can reduce adherence to treatment and lower quality of life. Healthcare professionals should prioritize patient perspectives and individualized treatment planning to address this issue.
Researchers found that 1% penciclovir cream is safe and well-tolerated when used to treat feline herpesvirus type 1-related eye infections. The cream maintained antiviral levels for over eight hours, suggesting twice-daily use could effectively manage the condition.
A potential new drug called RBM20-ASO has been shown to improve cardiac function in a mouse model of heart failure with preserved ejection fraction (HFpEF). The therapy reduces left ventricular stiffness and abnormal thickening of the heart muscle, even in the presence of comorbidities.
A team of UNLV researchers has engineered a new class of cannabidiol (CBD)-like medicines that show powerful seizure-reducing effects. The caraway-seed derived therapies offer a safer and more effective treatment for childhood seizure disorders than existing frontline therapies.
In a multicenter randomized clinical trial, rapid induction of injectable extended-release buprenorphine showed higher retention rates compared to standard induction. Administration of injection 2 after 1 week was well tolerated and reduced time below target therapeutic levels.
The International Society for Stem Cell Research (ISSCR) has released a comprehensive guide to accelerate the translation of human pluripotent stem cell-derived therapies into clinical trials and commercial use. The guidance outlines key principles and decision points for developing safe, effective, and regulatory-compliant products.
A large-scale observational study found that patients who continued taking ACEis or ARBs had a significantly lower risk of mortality and functional decline after non-cardiac surgeries. These benefits were most evident among patients undergoing orthopedic or gastrointestinal surgeries.
Researchers have developed a tool that can predict how patients with multiple sclerosis will respond to natalizumab treatment, allowing for targeted treatments with fewer side effects. The tool uses high-content imaging and machine learning to analyze cell morphology and identify individuals who are unlikely to respond to the medication.
Scientists at NYU Pain Research Center identified the EP2 receptor as the main cause of inflammatory pain but not inflammation. Blocking this receptor silenced pain responses without affecting inflammation, offering a new strategy for treating prostaglandin-mediated pain.
Leading researchers are advocating for increased diagnostics and treatment of Alzheimer's disease, citing significant advances in research and the availability of new medicines. The European Union has approved two medicines that slow the progression of mild dementia by removing amyloid plaques from the brain.
Researchers highlight NAD+ supplements as potential key to healthier ageing and disease prevention, but call for larger studies. Early trials report improvements in memory, movement, and metabolism.
Researchers at the University of Liverpool have discovered a groundbreaking new class of antibiotics called Novltex, which targets lipid II in bacterial cell walls. This innovative approach offers potent and durable protection against multidrug-resistant bacteria, addressing one of the biggest challenges in modern medicine.
A smartphone app, Med Safety, improved the reporting of suspected adverse drug reactions (ADRs) by 73% among healthcare workers in Uganda. This landmark trial provides robust evidence for digital pharmacovigilance systems in low- and middle-income countries.
A recent study found that two-thirds of clinical trial participants experienced complete remission from major depressive disorder five years after psilocybin-assisted therapy. The treatment also showed significant and large reduction in depression symptoms, with many participants reporting improved well-being measures.
Researchers create peptide hydrogel that controls drug release, improving treatment adherence and efficacy for conditions like tuberculosis and diabetes. The SABER platform uses reversible chemical bonds to slow down drug release, offering a promising solution for precise delivery.
A Finnish study found that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive to NSAIDs. Only a small number of patients benefited from the therapy, while a significant number experienced adverse effects.